首页> 外文期刊>Gastroenterology >Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers
【24h】

Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers

机译:零星早熟弥漫性胃癌具有高频率的体细胞CDH1改变,但与晚期发作癌症相比,体细胞突变突变的低频率

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND & AIMS: Early-onset gastric cancer, which develops in patients younger than most gastric cancers, is usually detected at advanced stages, has diffuse histologic features, and occurs more frequently in women. We investigated somatic genomic alterations associated with the unique characteristics of sporadic diffuse gastric cancers (DGCs) from younger patients. METHODS: We conducted whole exome and RNA sequence analyses of 80 resected DGC samples from patients 45 years old or younger in Korea. Patients with pathogenic germline mutations in CDH1, TP53, and ATM were excluded from the onset of this analysis, given our focus on somatic alterations. We used MutSig2CV to evaluate the significance of mutated genes. We recruited 29 additional early-onset Korean DGC samples and performed SNP6.0 array and targeted sequencing analyses of these 109 early-onset DGC samples (54.1% female, median age, 38 years). We compared the SNP6.0 array and targeted sequencing data of the 109 early-onset DGC samples with those from diffuse-type stomach tumor samples collected from 115 patients in Korea who were 46 years or older (late onset) at the time of diagnosis (controls; 29.6% female, median age, 67 years). We compared patient survival times among tumors from different subgroups and with different somatic mutations. We performed gene silencing of RHOA or CDH1 in DGC cells with small interfering RNAs for cell-based assays. RESULTS: We identified somatic mutations in the following genes in a significant number of early-onset DGCs: the cadherin 1 gene (CDH1), TP53, ARID1A, KRAS, PIK3CA, ERBB3, TGFBR1, FBXW7, RHOA, and MAP2K1. None of 109 early-onset DGC cases had pathogenic germline CDH1 mutations. A higher proportion of early-onset DGCs had mutations in CDH1 (42.2%) or TGFBR1 (7.3%) compared with control DGCs (17.4% and 0.9%, respectively) (P<.001 and P=.014 for CDH1 and TGFBR1, respectively). In contrast, a smaller proportion of early-onset DGCs contained mutations in RHOA (9.2%) than control DGCs (19.1%) (P=.033). Late-onset DGCs in The Cancer Genome Atlas also contained less frequent mutations in CDH1 and TGFBR1 and more frequent RHOA mutations, compared with early-onset DGCs. Early-onset DGCs from women contained significantly more mutations in CDH1 or TGFBR1 than early-onset DGCs from men. CDH1 alterations, but not RHOA mutations, were associated with shorter survival times in patients with early-onset DGCs (hazard ratio, 3.4; 95% confidence interval, 1.5 - 7.7). RHOA activity was reduced by an R5W substitution-the RHOA mutation most frequently detected in early-onset DGCs. Silencing of CDH1, but not RHOA, increased migratory activity of DGC cells. CONCLUSIONS: In an integrative genomic analysis, we found higher proportions of early-onset DGCs to contain somatic mutations in CDH1 or TGFBR1 compared with late-onset DGCs. However, a smaller proportion of early-onset DGCs contained somatic mutations in RHOA than late-onset DGCs. CDH1 alterations, but not RHOA mutations, were associated with shorter survival times of patients, which might account for the aggressive clinical course of early-onset gastric cancer. Female predominance in early-onset gastric cancer may be related to relatively high rates of somatic CDH1 and TGFBR1 mutations in this population.
机译:背景和目标:早盘胃癌,在比大多数胃癌的患者中,通常在晚期阶段检测到患者,具有弥漫性组织学特征,并且在女性中更频繁地发生。我们调查了与年轻患者的散发弥漫胃癌(DGCS)独特特征相关的体细胞基因组改变。方法:我们对韩国45岁或以下的患者进行了80个切除的DGC样本的全极端和RNA序列分析。鉴于我们对体细胞改变的关注,CDH1,TP53和ATM中病原种系突变的患者被排除在该分析的开始之外。我们使用Mutsig2CV来评估突变基因的意义。我们招聘了29个额外的早期韩国DGC样本,并进行了SNP6.0阵列和目标测序分析,这些109个早期性DGC样本(54.1%,女中位年龄,38岁)。我们将SNP6.0阵列和目标测序数据与来自于115名患者收集的胃肿瘤样本的阵列和目标测序数据进行比较。在诊断时为46岁或以上(控制;女性29.6%,中位年龄,67岁)。我们将患者生存时间与来自不同亚组的肿瘤和不同的体细胞突变进行了比较。我们在具有小干扰RNA的DGC细胞中对RHOA或CDH1进行了基因沉默,用于基于细胞的测定。结果:我们在大量早期发病DGC中鉴定了以下基因中的细胞突变:Cadherin 1基因(CDH1),TP53,ARID1A,KRAS,PIK3CA,ERBB3,TGFBR1,FBXW7,RHOA和MAP2K1。 109例早发性DGC病例中没有一个致病性系CDH1突变。与对照DGCs(分别为17.4%和0.9%)相比,较高比例的早熟DGCs在CDH1(42.2%)或TGFBR1(7.3%)中具有突变(分别为17.4%和0.9%)(用于CDH1和TGFBR1的P <.001和P = .014,分别)。相反,比对照DGCs(19.1%)(p = .033)含有较小的早熟DGCs含有突变(9.2%)的突变。与早期发病DGC相比,癌症基因组Atlas中的晚期DGC在CDH1和TGFBR1和更频繁的RHOA突变中含有较少的突变。来自女性的早期性DGCS在CDH1或TGFBR1中含有比早期发病的DGC在男性的高度突变。 CDH1改变但不是RHOA突变,与早期发病DGCS(危险比,3.4; 95%置信区间,1.5-7.7)的患者的存活时间短。 R5W替代 - 在早发性DGCs中最常检测到的RHOA突变减少了RHOA活性。 CDH1的沉默,但不是RHOA,增加了DGC细胞的迁移活性。结论:在综合基因组分析中,与晚期疾病DGCS相比,我们发现更高比例的早熟DGC在CDH1或TGFBR1中含有细胞突变。然而,较小比例的早熟DGCs在RHOA中含有比后期DGCs的体细胞突变。 CDH1改变但不是RhoA突变,与患者的较短生存时间相关联,这可能考虑了早盘胃癌的侵略性临床进程。早期胃癌中的女性优势可能与该群体中的体细胞CDH1和TGFBR1突变的相对高率有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号